![Patrick Volkert Vink](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Volkert Vink
Chairman at
ARCH BIOPARTNERS INC.
Net worth: 304 657 $ as of 2026-09-29
Profile
Patrick Volkert Vink is currently Chairman at Arch Biopartners, Inc. (since 2026), F2G Ltd. (since 2019), BiognoSYS AG (since 2020), Targovax Oy, Essential Pharmaceuticals LLC, Secura Bio, Inc., and Micreos BV.
Holds the position of Non-Executive Deputy Chairman at Avacta Group Plc (since 2026).
Serves as Independent Director at SQZ Biotechnologies Co. (since 2021) and Lead Independent Director at Spero Therapeutics, Inc. (since 2023).
Also Director at F2g Inc., Venture Partner at Forbion Capital Partners Management Holding BV, and Advisory Partner at Gyrus Capital SA (since 2020).
Former roles include Non-Executive Chairman at Acacia Pharma Ltd. and Acacia Pharma Group Ltd. (2016–2020), Chairman at Circio Holding ASA (2017–2020), Chairman at PIQUR Therapeutics AG, Chairman at NMD Pharma A (2015–2023), Chairman at Essential Pharmaceuticals Ltd., Non-Executive Director at Amryt Pharma Holdings Ltd. and Amryt Pharma PLC (2019–2023), Non-Executive Director at Arch Biopartners, Inc. (2016–2019), Independent Director at Santhera Pharmaceuticals Holding AG (2017–2023), Director at Inhibikase Therapeutics, Inc., Independent Non-Executive Director at Advanz Pharma Corp.
Ltd. (2016–2018), Chief Operating Officer & Executive Vice President at Cubist Pharmaceuticals LLC (2015), Vice President-International Business at Biogen, Inc. (2000–2002), Head-Business Franchise Biopharmaceuticals at Sandoz, Inc. (2002–2006), SVP, Global Head-Hospital Business & Biologics at Mylan, Inc. (2008–2012), Head-Worldwide Marketing at Sanofi-Synthelabo, Inc. (1997–2000), and Head-Global Business Franchise Biopharmaceuticals at Novartis Sandoz Thailand Ltd.
Education includes a doctorate from the University of Leiden (1988) and an MBA from the University of Rochester (1992).
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-01-14 | 181,600 ( 0.27% ) | 108 960 $ | 2026-09-29 | |
AVACTA GROUP PLC 0.02% | 2026-10-05 | 110,294 ( 0.02% ) | 104 947 $ | 2026-09-29 |
| 2026-06-22 | 75,000 ( 0.13% ) | 90 750 $ | 2026-09-29 |
Patrick Volkert Vink active positions
| Companies | Position | Start |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Director/Board Member | 2015-08-31 |
| SQZ BIOTECHNOLOGIES COMPANY | Director/Board Member | 2021-06-30 |
| ARCH BIOPARTNERS INC. | Chairman | 2026-01-14 |
| AVACTA GROUP PLC | Director/Board Member | 2026-07-05 |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Chairman | 2019-04-07 |
Essential Pharmaceuticals LLC
 Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Chairman | - |
F2g Inc.
 F2g Inc. Miscellaneous Commercial ServicesCommercial Services F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Director/Board Member | - |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Private Equity Investor | - |
Gyrus Capital SA
 Gyrus Capital SA Investment ManagersFinance Acts as an alternative investment manager | Private Equity Investor | 2020-06-24 |
| ░░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░ | - |
Former positions of Patrick Volkert Vink
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Education of Patrick Volkert Vink
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
75
1st degree connections
30
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 30 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops antibiotics to combat drug-resistant bacterial infections | Health Technology |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Health Technology |
Mylan, Inc.
 Mylan, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures generic pharmaceuticals | Health Technology |
Micreos BV
 Micreos BV Pharmaceuticals: MajorHealth Technology Operates as a biotech platform company that develops recombinant proteins for chronic dermatology conditions | Health Technology |
SQZ Biotechnologies Co.
 SQZ Biotechnologies Co. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cell therapies for patients with cancer, infectious diseases and serious conditions | Health Technology |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
University of Leiden
 University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avacta Group Plc
 Avacta Group Plc Miscellaneous Commercial ServicesCommercial Services Engages in the business of healthcare technology and consumables | Commercial Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Health Technology |
Sanofi-Synthelabo, Inc. | Health Technology |
Acacia Pharma Ltd.
 Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Provides supportive care product opportunities for post-surgical and cancer patients | Health Technology |
BiognoSYS AG
 BiognoSYS AG Packaged SoftwareTechnology Services Provides software and data platforms for life science researchers, biomarkers and drug developers | Technology Services |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Focuses on the development and commercialization of targeted cancer immunotherapy | Health Technology |
Arch Biopartners, Inc.
 Arch Biopartners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops novel drugs | Health Technology |
Inhibikase Therapeutics, Inc.
 Inhibikase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes small-molecule kinase inhibitor therapeutics for neurological diseases | Health Technology |
Circio Holding ASA
 Circio Holding ASA BiotechnologyHealth Technology Develops active immunotherapy cancer vaccines | Health Technology |
Spero Therapeutics, Inc.
 Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
Advanz Pharma Corp. Ltd.
 Advanz Pharma Corp. Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: MajorHealth Technology Engages in discovery and development of anti-cancer drugs | Health Technology |
Acacia Pharma Group Ltd.
 Acacia Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company that engages in developing and commercializing novel products for surgery, invasive procedures & chemotherapy | Health Technology |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for patients with rare and orphan diseases | Health Technology |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology Discovers and develops novel therapeutics for neuromuscular diseases | Health Technology |
Essential Pharmaceuticals LLC
Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Essential Pharmaceuticals Ltd.
 Essential Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Gyrus Capital SA
Gyrus Capital SA Investment ManagersFinance Acts as an alternative investment manager | Finance |
Secura Bio, Inc.
 Secura Bio, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products for oncology therapies | Health Technology |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company and develops and commercializing treatments for patients with rare & orphan diseases | Health Technology |
F2g Inc.
F2g Inc. Miscellaneous Commercial ServicesCommercial Services F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Commercial Services |
- Stock Market
- Insiders
- Patrick Volkert Vink
